-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Veracyte (NASDAQ:VCYT) Stock Price Down 8.6%
Veracyte (NASDAQ:VCYT) Stock Price Down 8.6%
Veracyte, Inc. (NASDAQ:VCYT – Get Rating) fell 8.6% during mid-day trading on Tuesday . The company traded as low as $19.00 and last traded at $19.08. 38,493 shares changed hands during mid-day trading, a decline of 95% from the average session volume of 717,068 shares. The stock had previously closed at $20.88.
Analyst Upgrades and Downgrades
A number of brokerages recently issued reports on VCYT. Needham & Company LLC raised their price objective on shares of Veracyte from $26.00 to $31.00 and gave the company a "buy" rating in a report on Wednesday, August 3rd. Raymond James raised their price objective on shares of Veracyte from $30.00 to $31.00 and gave the company an "outperform" rating in a report on Thursday, August 4th. One analyst has rated the stock with a sell rating and six have given a buy rating to the stock. According to data from MarketBeat.com, Veracyte has a consensus rating of "Moderate Buy" and a consensus target price of $42.50.
Get Veracyte alerts:Veracyte Trading Up 0.2 %
The firm's fifty day simple moving average is $23.62 and its 200-day simple moving average is $22.57.
Veracyte (NASDAQ:VCYT – Get Rating) last released its quarterly earnings results on Tuesday, August 2nd. The biotechnology company reported ($0.13) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.21) by $0.08. The firm had revenue of $72.86 million during the quarter, compared to analyst estimates of $67.37 million. Veracyte had a negative net margin of 18.13% and a negative return on equity of 4.05%. On average, sell-side analysts forecast that Veracyte, Inc. will post -0.8 earnings per share for the current year.Institutional Trading of Veracyte
Hedge funds have recently modified their holdings of the stock. Point72 Hong Kong Ltd bought a new stake in shares of Veracyte in the 1st quarter valued at $33,000. Assetmark Inc. increased its stake in shares of Veracyte by 90.3% in the 2nd quarter. Assetmark Inc. now owns 2,596 shares of the biotechnology company's stock valued at $52,000 after acquiring an additional 1,232 shares in the last quarter. Quantbot Technologies LP bought a new stake in shares of Veracyte in the 1st quarter valued at $73,000. Captrust Financial Advisors increased its stake in shares of Veracyte by 712.9% in the 2nd quarter. Captrust Financial Advisors now owns 3,219 shares of the biotechnology company's stock valued at $64,000 after acquiring an additional 2,823 shares in the last quarter. Finally, Lazard Asset Management LLC increased its stake in shares of Veracyte by 46.3% in the 1st quarter. Lazard Asset Management LLC now owns 3,410 shares of the biotechnology company's stock valued at $94,000 after acquiring an additional 1,079 shares in the last quarter.
Veracyte Company Profile
(Get Rating)
Veracyte, Inc operates as a diagnostics company worldwide. The company offers Afirma Genomic Sequencing Classifier and Xpression Atlas, which are used to determine patients with indeterminate results are benign to avoid unnecessary surgery; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; Percepta Genomic Sequencing Classifier and Percepta Nasal Swab Test for lung cancer diagnosis; Envisia Genomic Classifier for diagnosing interstitial lung disease, including idiopathic pulmonary fibrosis; and Immunoscore Colon Cancer test for colon cancer diagnosis.
Featured Articles
- Get a free copy of the StockNews.com research report on Veracyte (VCYT)
- Murphy USA Outperforming Other Mid-caps, But Is It A Buy Now?
- Has 3M Reached the Point of Being so Bad It's Good?
- Is This Medical Gear Maker Ready To Continue Its Rally?
- The Five (5) Hottest Stocks To Watch Ahead Of Q3 Earnings
- Has Take-Two Interactive Devolved into a One-Trick Pony?
Receive News & Ratings for Veracyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Veracyte and related companies with MarketBeat.com's FREE daily email newsletter.
Veracyte, Inc. (NASDAQ:VCYT – Get Rating) fell 8.6% during mid-day trading on Tuesday . The company traded as low as $19.00 and last traded at $19.08. 38,493 shares changed hands during mid-day trading, a decline of 95% from the average session volume of 717,068 shares. The stock had previously closed at $20.88.
在周二午盘交易中,Veracyte,Inc.(纳斯达克:VCYT-GET评级)下跌8.6%。该公司股价低至19.00美元,最新报19.08美元。午盘交易中,38,493股股票易手,较717,068股的平均成交量下降了95%。该股此前收盘价为20.88美元。
Analyst Upgrades and Downgrades
分析师升级和下调评级
A number of brokerages recently issued reports on VCYT. Needham & Company LLC raised their price objective on shares of Veracyte from $26.00 to $31.00 and gave the company a "buy" rating in a report on Wednesday, August 3rd. Raymond James raised their price objective on shares of Veracyte from $30.00 to $31.00 and gave the company an "outperform" rating in a report on Thursday, August 4th. One analyst has rated the stock with a sell rating and six have given a buy rating to the stock. According to data from MarketBeat.com, Veracyte has a consensus rating of "Moderate Buy" and a consensus target price of $42.50.
多家券商近日发布了有关VCYT的报告。Needham&Company LLC在8月3日星期三的一份报告中将Veracyte的股票目标价从26.00美元上调至31.00美元,并给予该公司“买入”评级。雷蒙德·詹姆斯在8月4日(星期四)的一份报告中将Veracyte的股票目标价从30.00美元上调至31.00美元,并给予该公司“跑赢大盘”的评级。一名分析师对该股的评级为卖出,六名分析师对该股的评级为买入。根据MarketBeat.com的数据,Veracyte的共识评级为“适度买入”,共识目标价为42.50美元。
Veracyte Trading Up 0.2 %
Veracyte股价上涨0.2%
The firm's fifty day simple moving average is $23.62 and its 200-day simple moving average is $22.57.
该公司的50日简单移动均线为23.62美元,200日简单移动均线为22.57美元。
Institutional Trading of Veracyte
Veracyte的机构交易
Hedge funds have recently modified their holdings of the stock. Point72 Hong Kong Ltd bought a new stake in shares of Veracyte in the 1st quarter valued at $33,000. Assetmark Inc. increased its stake in shares of Veracyte by 90.3% in the 2nd quarter. Assetmark Inc. now owns 2,596 shares of the biotechnology company's stock valued at $52,000 after acquiring an additional 1,232 shares in the last quarter. Quantbot Technologies LP bought a new stake in shares of Veracyte in the 1st quarter valued at $73,000. Captrust Financial Advisors increased its stake in shares of Veracyte by 712.9% in the 2nd quarter. Captrust Financial Advisors now owns 3,219 shares of the biotechnology company's stock valued at $64,000 after acquiring an additional 2,823 shares in the last quarter. Finally, Lazard Asset Management LLC increased its stake in shares of Veracyte by 46.3% in the 1st quarter. Lazard Asset Management LLC now owns 3,410 shares of the biotechnology company's stock valued at $94,000 after acquiring an additional 1,079 shares in the last quarter.
对冲基金最近调整了对该股的持有量。Point72 Hong Kong Ltd在第一季度购买了Veracyte价值3.3万美元的新股。AssetMark Inc.在第二季度增持了Veracyte股票90.3%。AssetMark Inc.现在持有这家生物技术公司2,596股股票,价值52,000美元,该公司在上个季度又收购了1,232股。Quantbot Technologies LP在第一季度购买了Veracyte的新股份,价值7.3万美元。CapTrust Financial Advisors在第二季度增持了Veracyte股票712.9%。CapTrust Financial Advisors在上个季度增持了2,823股后,现在持有这家生物技术公司3219股股票,价值6.4万美元。最后,Lazard Asset Management LLC在第一季度增持了Veracyte股票46.3%。Lazard Asset Management LLC现在拥有3410股这家生物技术公司的股票,价值94,000美元,上个季度又购买了1,079股。
Veracyte Company Profile
Veracyte公司简介
(Get Rating)
(获取评级)
Veracyte, Inc operates as a diagnostics company worldwide. The company offers Afirma Genomic Sequencing Classifier and Xpression Atlas, which are used to determine patients with indeterminate results are benign to avoid unnecessary surgery; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; Percepta Genomic Sequencing Classifier and Percepta Nasal Swab Test for lung cancer diagnosis; Envisia Genomic Classifier for diagnosing interstitial lung disease, including idiopathic pulmonary fibrosis; and Immunoscore Colon Cancer test for colon cancer diagnosis.
Veracyte,Inc.是一家全球性的诊断公司。该公司提供Afirma基因组测序分类器和Xpression Atlas,用于确定结果不确定的患者是否为良性疾病,以避免不必要的手术;解密前列腺癌活检和根治性前列腺癌切除术;Prosigna乳腺癌检测用于乳腺癌诊断;Percepta基因组测序分类器和Percepta鼻拭子测试用于肺癌诊断;Envisia基因组分类器用于诊断间质性肺部疾病,包括特发性肺纤维化;免疫结肠癌检测用于结肠癌诊断。
Featured Articles
专题文章
- Get a free copy of the StockNews.com research report on Veracyte (VCYT)
- Murphy USA Outperforming Other Mid-caps, But Is It A Buy Now?
- Has 3M Reached the Point of Being so Bad It's Good?
- Is This Medical Gear Maker Ready To Continue Its Rally?
- The Five (5) Hottest Stocks To Watch Ahead Of Q3 Earnings
- Has Take-Two Interactive Devolved into a One-Trick Pony?
- 免费获取StockNews.com关于Veracyte的研究报告(VCyT)
- 墨菲美国的表现好于其他中型股,但它现在值得吗?
- 3M已经到了坏到好的地步了吗?
- 这家医疗设备制造商准备好继续反弹了吗?
- 第三季度财报公布前最值得关注的五(5)只股票
- Take-Two Interactive是否已经退化为一招小马?
Receive News & Ratings for Veracyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Veracyte and related companies with MarketBeat.com's FREE daily email newsletter.
接受Veracyte Daily的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对Veracyte和相关公司的最新新闻和分析师评级的每日简要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧